MA41633B1 - Composés amide en tant qu'agonistes du récepteur 5-ht4 - Google Patents
Composés amide en tant qu'agonistes du récepteur 5-ht4Info
- Publication number
- MA41633B1 MA41633B1 MA41633A MA41633A MA41633B1 MA 41633 B1 MA41633 B1 MA 41633B1 MA 41633 A MA41633 A MA 41633A MA 41633 A MA41633 A MA 41633A MA 41633 B1 MA41633 B1 MA 41633B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- receptor agonists
- amide compounds
- relates
- hydroxytryptamine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
La présente invention concerne des composés de formule (i), y compris des stéréoisomères et des sels pharmaceutiquement acceptables de ceux-ci. Cette invention concerne en outre des procédés de fabrication de ces composés et de compositions pharmaceutiques comprenant ces composés. Les composés de cette invention sont utiles dans le traitement de différents troubles liés à des agonistes du récepteur de 5-hydroxytryptamine 4 (5-ht4).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN709CH2015 | 2015-02-13 | ||
| PCT/IN2016/000008 WO2016128990A1 (fr) | 2015-02-13 | 2016-01-07 | Composés d'amide en tant qu'agonistes du récepteur de 5-ht4 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA41633A MA41633A (fr) | 2019-05-15 |
| MA41633B1 true MA41633B1 (fr) | 2019-07-31 |
Family
ID=55588327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA41633A MA41633B1 (fr) | 2015-02-13 | 2016-01-07 | Composés amide en tant qu'agonistes du récepteur 5-ht4 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US9957257B2 (fr) |
| EP (1) | EP3265459B1 (fr) |
| JP (1) | JP6487564B2 (fr) |
| KR (1) | KR101966576B1 (fr) |
| CN (1) | CN107406434B (fr) |
| AU (1) | AU2016217461B2 (fr) |
| BR (1) | BR112017017275A2 (fr) |
| CA (1) | CA2975973C (fr) |
| CY (1) | CY1121898T1 (fr) |
| DK (1) | DK3265459T3 (fr) |
| EA (1) | EA034618B1 (fr) |
| ES (1) | ES2734734T3 (fr) |
| HR (1) | HRP20191179T1 (fr) |
| HU (1) | HUE045667T2 (fr) |
| IL (1) | IL253848B (fr) |
| LT (1) | LT3265459T (fr) |
| MA (1) | MA41633B1 (fr) |
| MD (1) | MD3265459T2 (fr) |
| ME (1) | ME03430B (fr) |
| MX (1) | MX368214B (fr) |
| NZ (1) | NZ734400A (fr) |
| PL (1) | PL3265459T3 (fr) |
| PT (1) | PT3265459T (fr) |
| RS (1) | RS59066B1 (fr) |
| SG (1) | SG11201706501VA (fr) |
| SI (1) | SI3265459T1 (fr) |
| SM (1) | SMT201900398T1 (fr) |
| TR (1) | TR201909997T4 (fr) |
| WO (1) | WO2016128990A1 (fr) |
| ZA (1) | ZA201705292B (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2780015B1 (fr) | 2011-11-18 | 2017-01-04 | Heptares Therapeutics Limited | Agonistes du récepteur muscarinique m1 |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| GB201709652D0 (en) * | 2017-06-16 | 2017-08-02 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| CN110818661B (zh) * | 2019-12-02 | 2021-08-06 | 上海再启生物技术有限公司 | 5-ht4受体激动剂的关键中间体4-氨基-5-卤苯并呋喃-7-羧酸的制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004026095D1 (de) | 2003-11-24 | 2010-04-29 | Pfizer | Chinoloncarbonsäureverbindungen mit 5-ht4-rezeptoragonistischer wirkung |
| WO2005092882A1 (fr) * | 2004-03-01 | 2005-10-06 | Pfizer Japan, Inc. | Derives de 4-amino-5-halogeno-benzamide utiles comme agonistes du recepteur 5-ht4 dans le traitement des troubles gastro-intestinaux, du systeme nerveux central, neurologiques et cardio-vasculaires |
| CA2598516C (fr) | 2005-02-25 | 2010-05-11 | Pfizer Inc. | Derives de benzisoxazole |
| CA2615611C (fr) | 2005-07-22 | 2011-09-27 | Pfizer Inc. | Derives de l'indazole |
| WO2007048643A1 (fr) * | 2005-10-28 | 2007-05-03 | Glaxo Group Limited | Nouveau composé |
| GB0525661D0 (en) * | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Novel compounds |
| GB0603550D0 (en) * | 2006-02-22 | 2006-04-05 | Glaxo Group Ltd | Novel compounds |
| JP6023926B2 (ja) * | 2010-02-12 | 2016-11-09 | 株式会社ＡｓｋＡｔ | 認知症治療のための５−ｈｔ４受容体アゴニスト |
| CA2788656A1 (fr) | 2010-02-16 | 2011-08-25 | Pfizer Inc. | (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl) piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ole, agoniste partiel des recepteurs 5-ht4 |
| PT2758394E (pt) * | 2011-09-19 | 2015-04-22 | Suven Life Sciences Ltd | Compostos heteroarilo como ligandos de recetores 5-ht4 |
| CN105164119B (zh) * | 2013-03-20 | 2017-12-08 | 苏文生命科学有限公司 | 作为5‑ht4受体激动剂的5‑氨基‑喹啉‑8‑甲酰胺衍生物 |
| MX368017B (es) * | 2013-12-16 | 2019-09-13 | Suven Life Sciences Ltd | Compuestos de indazol como agonistas del receptor de 5-ht4. |
-
2016
- 2016-01-07 SG SG11201706501VA patent/SG11201706501VA/en unknown
- 2016-01-07 SM SM20190398T patent/SMT201900398T1/it unknown
- 2016-01-07 MA MA41633A patent/MA41633B1/fr unknown
- 2016-01-07 MD MDE20180052T patent/MD3265459T2/ro not_active IP Right Cessation
- 2016-01-07 DK DK16711355.4T patent/DK3265459T3/da active
- 2016-01-07 PL PL16711355T patent/PL3265459T3/pl unknown
- 2016-01-07 HR HRP20191179TT patent/HRP20191179T1/hr unknown
- 2016-01-07 EA EA201791829A patent/EA034618B1/ru unknown
- 2016-01-07 MX MX2017010348A patent/MX368214B/es active IP Right Grant
- 2016-01-07 SI SI201630311T patent/SI3265459T1/sl unknown
- 2016-01-07 JP JP2017542107A patent/JP6487564B2/ja not_active Expired - Fee Related
- 2016-01-07 RS RS20190836A patent/RS59066B1/sr unknown
- 2016-01-07 NZ NZ734400A patent/NZ734400A/en not_active IP Right Cessation
- 2016-01-07 WO PCT/IN2016/000008 patent/WO2016128990A1/fr not_active Ceased
- 2016-01-07 ES ES16711355T patent/ES2734734T3/es active Active
- 2016-01-07 ME MEP-2019-190A patent/ME03430B/fr unknown
- 2016-01-07 KR KR1020177025584A patent/KR101966576B1/ko not_active Expired - Fee Related
- 2016-01-07 HU HUE16711355A patent/HUE045667T2/hu unknown
- 2016-01-07 TR TR2019/09997T patent/TR201909997T4/tr unknown
- 2016-01-07 PT PT16711355T patent/PT3265459T/pt unknown
- 2016-01-07 LT LTEP16711355.4T patent/LT3265459T/lt unknown
- 2016-01-07 AU AU2016217461A patent/AU2016217461B2/en not_active Ceased
- 2016-01-07 CN CN201680015614.4A patent/CN107406434B/zh not_active Expired - Fee Related
- 2016-01-07 BR BR112017017275A patent/BR112017017275A2/pt not_active IP Right Cessation
- 2016-01-07 EP EP16711355.4A patent/EP3265459B1/fr active Active
- 2016-01-07 CA CA2975973A patent/CA2975973C/fr not_active Expired - Fee Related
- 2016-01-07 US US15/549,663 patent/US9957257B2/en active Active
-
2017
- 2017-08-04 ZA ZA2017/05292A patent/ZA201705292B/en unknown
- 2017-08-06 IL IL253848A patent/IL253848B/en active IP Right Grant
-
2019
- 2019-07-10 CY CY20191100739T patent/CY1121898T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41633B1 (fr) | Composés amide en tant qu'agonistes du récepteur 5-ht4 | |
| MA44674B1 (fr) | Inhibiteurs de bromodomaine | |
| MA40123A1 (fr) | Pyrimidines utilisées en tant qu'inhibiteurs du facteur xia | |
| MA46357B1 (fr) | Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur | |
| MA40225B1 (fr) | Composés dihydroisoquinolinone substitués | |
| MA39898B1 (fr) | Composés 4-amino-imidazoquinoline | |
| MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
| MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
| MA42145B1 (fr) | Triazoles agonistes du récepteur apj | |
| MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA39995B1 (fr) | Composés destinés à traiter l'amyotrophie spinale | |
| MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
| EA201692260A1 (ru) | Соединения 1,3,4-тиадиазола и их применение в лечении рака | |
| MA43913B1 (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
| EA202092146A1 (ru) | Производные пиразотетрагидроизохинолина в качестве положительных модуляторов допаминового d1 рецептора | |
| MA42769B1 (fr) | Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1 | |
| EA201791480A1 (ru) | Новые производные бензимидазола в качестве антигистаминных агентов | |
| NZ720879A (en) | Indazole compounds as 5-ht4 receptor agonists | |
| MA39229A1 (fr) | Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines | |
| EA201991990A1 (ru) | Фармацевтические композиции для комбинированной терапии | |
| MA41975B1 (fr) | Derives d'aminohydrothiazine fusionnee contenant du tetrahydrofurane utiles dans le traitement de la maladie d'alzheimer | |
| EA201290532A1 (ru) | Бициклические тиазолы в качестве аллостерических модуляторов рецепторов mglur5 | |
| MA39533A1 (fr) | Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives | |
| MA44383B1 (fr) | Un derivé de 4-(3-pyrazolylamino)-benzimidazole en tant qu'inhibiteur de jak1 pour le traitement du cancer | |
| MA44503B1 (fr) | Composés de pyrrolotriazine en tant qu'inhibiteurs de tam |